Sagimet Biosciences reported preliminary Q1 2026 cash position of $104.5 million and announced plans to initiate Phase 3 trial of denifanstat for U.S. acne in 2H 2026 while pausing MASH development pending non-dilutive funding.
Key takeaways
Preliminary unaudited cash, cash equivalents and marketable securities of $104.5 million as of March 31, 2026.
Phase 3 clinical trial of denifanstat in moderate to severe acne for U.S. planned to initiate in 2H 2026 subject to IND clearance.
First-in-human Phase 1 trial of TVB-3567 ongoing with Phase 2 acne trial anticipated in 2H 2026.
Further MASH development paused until securing non-dilutive funding.
Ascletis reported positive long-term safety data from open-label Phase 3 acne trial in China.
Appointment of Andreas Grauer as Chief Medical Officer in April 2026.